Jacobs Scores in Ireland

Jacobs have announced that they will provide Genzyme Corp. with concept development, detailed design, and construction management for Genzyme's manufacturing capacity expansion in Waterford, Ireland. The contract value has not been disclosed to Contractor's Unlimited.

To support the strong growth of existing products and the launch of products within its development pipeline, Genzyme's 120,000-square-foot Waterford facility conversion will include the manufacture of the tablet formulation of RenagelŪ (a kidney disease treatment for dialysis patients) along with future development of a multiproduct manufacturing capability such as a biologics fill and finishing plant and bulk pharmaceutical manufacturing.

Genzyme Chairman and Chief Executive Officer Henri A. Termeer stated, "Our decision to expand our capability in Ireland will substantially strengthen our world class biomanufacturing infrastructure and expertise that we have developed over two decades."

In making the announcement, Jacobs Group Vice President John McLachlan stated, "We are excited to be a part of Genzyme's global strategy for significant expansion in their manufacturing capabilities. We will deliver a state-of-the-art facility conforming to the 21st century production and environmental standards, which is of prime interest to our client."

Back